CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RSPH3 (ImmuneEditome ID:83861)

1. Gene summary of enriched editing regions for RSPH3

check button Gene summary
Gene informationGene symbol

RSPH3

Gene ID

83861

GeneSynonymsCILD32|RSHL2|RSP3|dJ111C20.1
GeneCytomap

6q25.3

GeneTypeprotein-coding
GeneDescriptionradial spoke head protein 3 homolog|A-kinase anchor protein RSPH3|radial spoke 3 homolog|radial spoke head 3 homolog|radial spoke head-like protein 2
GeneModificationdate20230404
UniprotIDA0A0C4DG29;A0A0C4DFU3
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr6:158973317-158977135:-ENST00000607398.1ENSG00000130363.10RSPH3ncRNA_exonicAluSp,L2b,L3b,MIRc,AluSc5,AluJb,AluSc,L1ME3Gchr6:158973317-158977135:-.alignment


Top

2. Tumor-specific enriched editing regions for RSPH3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr6:158973317-158977135:-BRCAEER1.0294e-08image
ENSG00000130363.10,RSPH3BRCAEAG1.9750e-07image
chr6:158973317-158977135:-COADEER4.2251e-03image
ENSG00000130363.10,RSPH3COADEAG4.5410e-03image
chr6:158973317-158977135:-HNSCEER1.5582e-14image
ENSG00000130363.10,RSPH3HNSCEAG2.2549e-14image
chr6:158973317-158977135:-KICHEER7.4274e-08image
ENSG00000130363.10,RSPH3KICHEAG7.4274e-08image
chr6:158973317-158977135:-KIRCEER4.4422e-06image
ENSG00000130363.10,RSPH3KIRCEAG1.8518e-05image
chr6:158973317-158977135:-KIRPEER2.7283e-02image
ENSG00000130363.10,RSPH3KIRPEAG2.4156e-02image
chr6:158973317-158977135:-THCAEER1.4642e-19image
ENSG00000130363.10,RSPH3THCAEAG1.6051e-19image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000130363.10,RSPH3BLCAPathEAG2.3799e-022.5492e-020.1168image
chr6:158973317-158977135:-BLCAPathEER1.1454e-021.9123e-020.1226image
ENSG00000130363.10,RSPH3LIHCPathEAG2.4842e-022.7607e-03-0.2276image
ENSG00000130363.10,RSPH3STADPathEAG2.6728e-024.1274e-020.1096image
ENSG00000130363.10,RSPH3THCAPathEAG1.0645e-043.4198e-040.1595image
chr6:158973317-158977135:-THCAPathEER5.1516e-052.4975e-040.1631image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr6:158973317-158977135:-PCPGEER1.6947e-023.5355e-024.9415e+14image
ENSG00000130363.10,RSPH3PCPGEAG1.6947e-023.9216e-027.8877e+32image

Top

3. Enriched editing regions and immune related genes for RSPH3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr6:158973317-158977135:-STADEERENSG00000134339,SAA20.18757.2918e-031.1334e-220.4807imageNNSAA2GSVA_HALLMARK_UV_RESPONSE_DN
chr6:158973317-158977135:-STADEERENSG00000255071,SAA2-SAA40.15042.5142e-023.5622e-230.4856imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr6:158973317-158977135:-STADEERENSG00000173432,SAA10.15653.1980e-024.8109e-230.4844imageNNSAA1T_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr6:158973317-158977135:-KICHEERENSG00000104611,SH2D4A-0.56282.3602e-021.3930e-05-0.5105imageNFBL;TARDBPNAMonocytesGSVA_HALLMARK_PROTEIN_SECRETION
chr6:158973317-158977135:-KICHEERENSG00000174607,UGT8-0.57552.3602e-026.7256e-07-0.5712imageNFBL;TARDBPNAT_cells_CD4_memory_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr6:158973317-158977135:-KICHEERENSG00000177889,UBE2N-0.57112.4066e-026.2258e-06-0.5278imageNFBL;TARDBPUBE2NT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr6:158973317-158977135:-KICHEERENSG00000135108,FBXO21-0.57222.4066e-025.0507e-06-0.5322imageNFBL;TARDBPNAT_cells_CD4_memory_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chr6:158973317-158977135:-KICHEERENSG00000163257,DCAF16-0.55902.6025e-022.6208e-05-0.4963imageNFBL;TARDBPNADendritic_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr6:158973317-158977135:-KICHEERENSG00000277782,RP11-775C24.50.54862.6643e-024.3937e-080.6171imageNNNANK_cells_restingGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr6:158973317-158977135:-KICHEERENSG00000196646,ZNF136-0.54972.9803e-028.7249e-06-0.5207imageNFBL;TARDBPNADendritic_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

4. Enriched editing regions and immune related splicing for RSPH3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000130363.10,RSPH3
BLCAEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.45411.4909e-143.4373e-19-0.4454imageNACIN1;ADAR;AIFM1;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YWHAGPRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr6:158973317-158977135:-
BLCAEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.48981.8173e-171.8534e-22-0.4808imageNFBL;TARDBPPRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr6:158973317-158977135:-
BLCAEERIRENSG00000076928.13chr1941897314:41897326:41897945:41897982-0.32645.2674e-104.2689e-13-0.4067imageNFBL;TARDBPNAT_cells_CD4_memory_activatedGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr6:158973317-158977135:-
BLCAEERIRENSG00000111679.12chr126951261:6951520:6951608:6951731-0.32003.7823e-096.1892e-14-0.4091imageNFBL;TARDBPPTPN6Dendritic_cells_activatedGSVA_HALLMARK_COMPLEMENT
chr6:158973317-158977135:-
BLCAEERIRENSG00000130985.12chrX47193828:47198355:47198802:47198919-0.27253.0856e-073.6329e-12-0.4004imageNFBL;TARDBPNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000130363.10,RSPH3
BLCAEAGIRENSG00000076928.13chr1941897314:41897326:41897945:41897982-0.32051.5756e-092.7433e-13-0.4097imageNADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YWHAGNAT_cells_CD4_memory_activatedGSVA_HALLMARK_ALLOGRAFT_REJECTION
ENSG00000130363.10,RSPH3
GBMEAGMEXENSG00000129657.10chr1777215935:77215958:77216075:77216101:77216114:77216387:77216413:77216802-0.24129.3742e-038.4348e-07-0.4270imageNACIN1;ADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPL;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YWHAGNAT_cells_CD4_memory_activated
chr6:158973317-158977135:-
GBMEERMEXENSG00000129657.10chr1777215935:77215958:77216075:77216101:77216114:77216387:77216413:77216802-0.24008.6386e-038.4114e-07-0.4270imageNFBL;TARDBPNAT_cells_CD4_memory_activated
ENSG00000130363.10,RSPH3
KIRPEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.39876.8213e-091.8010e-13-0.4165imageNACIN1;ADAR;AIFM1;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YWHAGPRKCSHT_cells_CD8GSVA_HALLMARK_KRAS_SIGNALING_DN
chr6:158973317-158977135:-
KIRPEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.40414.0586e-098.9879e-14-0.4212imageNFBL;TARDBPPRKCSHT_cells_CD8GSVA_HALLMARK_KRAS_SIGNALING_DN

More results



Top

5. Enriched editing regions and immune infiltration for RSPH3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr6:158973317-158977135:-ACCEERB_cells_memory2.6900e-020.2522image
ENSG00000130363.10,RSPH3ACCEAGB_cells_memory2.6900e-020.2522image
chr6:158973317-158977135:-BLCAEERMacrophages_M14.3522e-090.3011image
ENSG00000130363.10,RSPH3BLCAEAGMacrophages_M13.9033e-090.3016image
chr6:158973317-158977135:-BRCAEERMacrophages_M15.5897e-070.1520image
ENSG00000130363.10,RSPH3BRCAEAGMacrophages_M15.8620e-060.1378image
chr6:158973317-158977135:-CESCEERMacrophages_M12.8124e-030.1757image
ENSG00000130363.10,RSPH3CESCEAGMacrophages_M13.6956e-030.1706image
chr6:158973317-158977135:-CHOLEERPlasma_cells1.1271e-020.4357image
ENSG00000130363.10,RSPH3CHOLEAGMacrophages_M22.7659e-02-0.3833image
chr6:158973317-158977135:-COADEERT_cells_CD82.4069e-030.1867image
ENSG00000130363.10,RSPH3COADEAGT_cells_CD82.2778e-030.1877image
chr6:158973317-158977135:-ESCAEERDendritic_cells_resting2.3258e-02-0.1788image
ENSG00000130363.10,RSPH3ESCAEAGDendritic_cells_resting2.5812e-02-0.1757image
chr6:158973317-158977135:-GBMEERMast_cells_resting1.4448e-020.1943image
ENSG00000130363.10,RSPH3GBMEAGMast_cells_resting1.3468e-020.1962image
chr6:158973317-158977135:-HNSCEERMacrophages_M22.5810e-060.2170image
ENSG00000130363.10,RSPH3HNSCEAGMacrophages_M23.3116e-060.2146image
chr6:158973317-158977135:-KIRCEERT_cells_CD86.7330e-060.2278image
ENSG00000130363.10,RSPH3KIRCEAGMast_cells_resting1.7456e-05-0.2176image
chr6:158973317-158977135:-KIRPEERT_cells_CD4_memory_resting3.2483e-03-0.1732image
ENSG00000130363.10,RSPH3KIRPEAGT_cells_CD4_memory_resting3.9948e-03-0.1694image
chr6:158973317-158977135:-LAMLEERT_cells_CD4_memory_activated3.1662e-040.3314image
ENSG00000130363.10,RSPH3LAMLEAGT_cells_CD4_memory_activated2.9847e-040.3327image
chr6:158973317-158977135:-LGGEERMonocytes7.9449e-050.1735image
ENSG00000130363.10,RSPH3LGGEAGMonocytes4.4464e-050.1794image
chr6:158973317-158977135:-LIHCEERMonocytes4.0804e-020.1531image
ENSG00000130363.10,RSPH3LIHCEAGMonocytes4.8337e-020.1458image
chr6:158973317-158977135:-LUADEERT_cells_CD4_memory_activated1.6320e-070.2353image
ENSG00000130363.10,RSPH3LUADEAGT_cells_CD4_memory_activated1.0230e-060.2200image
chr6:158973317-158977135:-LUSCEERT_cells_CD4_memory_activated8.4292e-050.1817image
ENSG00000130363.10,RSPH3LUSCEAGT_cells_CD4_memory_activated1.0819e-040.1790image
chr6:158973317-158977135:-MESOEERT_cells_follicular_helper8.3563e-030.2948image
ENSG00000130363.10,RSPH3MESOEAGT_cells_follicular_helper9.9431e-030.2884image
chr6:158973317-158977135:-OVEERMacrophages_M02.2111e-04-0.2164image
ENSG00000130363.10,RSPH3OVEAGMacrophages_M01.7006e-03-0.1841image
chr6:158973317-158977135:-PAADEERMast_cells_activated3.7106e-020.1586image
chr6:158973317-158977135:-PCPGEERPlasma_cells1.9173e-030.2317image
ENSG00000130363.10,RSPH3PCPGEAGPlasma_cells2.0440e-030.2303image
chr6:158973317-158977135:-PRADEERT_cells_regulatory_(Tregs)2.8836e-060.2083image
ENSG00000130363.10,RSPH3PRADEAGT_cells_regulatory_(Tregs)2.4773e-060.2097image
chr6:158973317-158977135:-READEERB_cells_memory2.4138e-020.2363image
ENSG00000130363.10,RSPH3READEAGB_cells_memory2.4138e-020.2363image
chr6:158973317-158977135:-SARCEERNeutrophils3.4138e-040.2399image
ENSG00000130363.10,RSPH3SARCEAGNeutrophils3.4075e-040.2399image
chr6:158973317-158977135:-SKCMEERT_cells_CD81.7103e-040.2007image
ENSG00000130363.10,RSPH3SKCMEAGT_cells_CD86.8339e-040.1807image
chr6:158973317-158977135:-STADEERT_cells_CD82.9566e-030.1545image
ENSG00000130363.10,RSPH3STADEAGT_cells_CD86.0420e-030.1429image
chr6:158973317-158977135:-TGCTEERMacrophages_M21.9568e-04-0.4368image
ENSG00000130363.10,RSPH3TGCTEAGMacrophages_M22.1486e-04-0.4344image
chr6:158973317-158977135:-THCAEERDendritic_cells_resting3.7631e-060.2049image
ENSG00000130363.10,RSPH3THCAEAGDendritic_cells_resting2.2756e-060.2094image
chr6:158973317-158977135:-THYMEERDendritic_cells_resting1.8726e-02-0.2348image
ENSG00000130363.10,RSPH3THYMEAGDendritic_cells_resting1.4818e-02-0.2431image
chr6:158973317-158977135:-UCECEERDendritic_cells_activated1.2203e-030.2497image
ENSG00000130363.10,RSPH3UCECEAGT_cells_CD4_memory_resting2.7227e-03-0.2319image
chr6:158973317-158977135:-UCSEERMonocytes3.1541e-02-0.2903image
ENSG00000130363.10,RSPH3UCSEAGMonocytes2.0116e-02-0.3127image


Top

6. Enriched editing regions and immune gene sets for RSPH3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr6:158973317-158977135:-BLCAEER3.3864e-03image1.6041e-070.2701image
ENSG00000130363.10,RSPH3BLCAEAG3.1295e-03image5.6655e-070.2579image
chr6:158973317-158977135:-HNSCEER4.4909e-02image9.4701e-030.1207image
ENSG00000130363.10,RSPH3HNSCEAG4.6613e-02image9.6889e-030.1204image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr6:158973317-158977135:-BLCAEER3.5311e-040.18608.5105e-030.13755.0718e-030.14641.0704e-030.1706image
ENSG00000130363.10,RSPH3BLCAEAG1.0425e-030.17071.3054e-020.12966.9811e-030.14081.5635e-030.1648image
chr6:158973317-158977135:-BRCAEER6.5557e-070.15119.4172e-100.18533.5123e-020.06431.3282e-060.1469image
ENSG00000130363.10,RSPH3BRCAEAG5.1439e-070.15253.3542e-110.20051.8936e-020.07167.5209e-070.1503image
chr6:158973317-158977135:-LUADEER3.4410e-070.22922.4900e-050.19041.6048e-040.17076.0760e-070.2244image
ENSG00000130363.10,RSPH3LUADEAG1.0442e-060.21983.1529e-050.18802.9595e-040.16384.6562e-070.2267image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr6:158973317-158977135:-ACCGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.9465e-020.2658image
ENSG00000130363.10,RSPH3ACCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.9465e-020.2658image
chr6:158973317-158977135:-BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER5.6306e-140.3799image
ENSG00000130363.10,RSPH3BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.3850e-130.3704image
chr6:158973317-158977135:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.7960e-390.3827image
ENSG00000130363.10,RSPH3BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.9346e-370.3753image
ENSG00000130363.10,RSPH3CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.1362e-080.3162image
chr6:158973317-158977135:-CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3410e-090.3481image
ENSG00000130363.10,RSPH3CHOLGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG4.3738e-03-0.4834image
chr6:158973317-158977135:-CHOLGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER4.2170e-03-0.4851image
ENSG00000130363.10,RSPH3COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG6.1620e-050.2449image
chr6:158973317-158977135:-COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER5.5285e-050.2464image
chr6:158973317-158977135:-ESCAGSVA_HALLMARK_KRAS_SIGNALING_DNEER8.3373e-03-0.2073image
ENSG00000130363.10,RSPH3ESCAGSVA_HALLMARK_KRAS_SIGNALING_DNEAG6.1094e-03-0.2152image
ENSG00000130363.10,RSPH3GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.3994e-030.2520image
chr6:158973317-158977135:-GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3884e-030.2522image
ENSG00000130363.10,RSPH3HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6560e-130.3344image
chr6:158973317-158977135:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0864e-130.3368image
chr6:158973317-158977135:-KICHGSVA_HALLMARK_PROTEIN_SECRETIONEER6.1829e-03-0.3362image
ENSG00000130363.10,RSPH3KICHGSVA_HALLMARK_PROTEIN_SECRETIONEAG6.1829e-03-0.3362image
ENSG00000130363.10,RSPH3KIRCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.8913e-090.3008image
chr6:158973317-158977135:-KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.1581e-100.3143image
ENSG00000130363.10,RSPH3KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.6717e-060.2694image
chr6:158973317-158977135:-KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEER5.5139e-060.2646image
chr6:158973317-158977135:-LAMLGSVA_HALLMARK_ANGIOGENESISEER2.8663e-020.2050image
ENSG00000130363.10,RSPH3LAMLGSVA_HALLMARK_ANGIOGENESISEAG3.0640e-020.2026image
ENSG00000130363.10,RSPH3LGGGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG4.8307e-080.2383image
chr6:158973317-158977135:-LGGGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER2.9431e-080.2420image
chr6:158973317-158977135:-LIHCGSVA_HALLMARK_NOTCH_SIGNALINGEER4.4905e-04-0.2596image
ENSG00000130363.10,RSPH3LIHCGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.1831e-05-0.3074image
ENSG00000130363.10,RSPH3LUADGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.8036e-110.2992image
chr6:158973317-158977135:-LUADGSVA_HALLMARK_MTORC1_SIGNALINGEER8.4823e-120.3039image
chr6:158973317-158977135:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5280e-070.2368image
ENSG00000130363.10,RSPH3LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.8947e-070.2283image
chr6:158973317-158977135:-MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER4.5967e-040.3850image
ENSG00000130363.10,RSPH3MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG6.1174e-040.3772image
ENSG00000130363.10,RSPH3OVGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG5.3964e-090.3353image
chr6:158973317-158977135:-OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.5663e-100.3661image
ENSG00000130363.10,RSPH3PAADGSVA_HALLMARK_SPERMATOGENESISEAG1.2496e-02-0.1896image
chr6:158973317-158977135:-PAADGSVA_HALLMARK_SPERMATOGENESISEER5.1846e-03-0.2116image
ENSG00000130363.10,RSPH3PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG9.5587e-060.3259image
chr6:158973317-158977135:-PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.3992e-060.3410image
ENSG00000130363.10,RSPH3PRADGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.2510e-07-0.2299image
chr6:158973317-158977135:-PRADGSVA_HALLMARK_PROTEIN_SECRETIONEER2.5593e-07-0.2289image
ENSG00000130363.10,RSPH3READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG7.2870e-030.2795image
chr6:158973317-158977135:-READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER7.2870e-030.2795image
chr6:158973317-158977135:-SARCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER1.0806e-050.2925image
ENSG00000130363.10,RSPH3SARCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG6.9504e-060.2985image
ENSG00000130363.10,RSPH3SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.2295e-040.1961image
chr6:158973317-158977135:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.2655e-050.2135image
chr6:158973317-158977135:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.8757e-070.2569image
ENSG00000130363.10,RSPH3STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4668e-060.2480image
chr6:158973317-158977135:-TGCTGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.0959e-040.4244image
ENSG00000130363.10,RSPH3TGCTGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG3.8080e-040.4187image
chr6:158973317-158977135:-THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER6.8252e-260.4463image
ENSG00000130363.10,RSPH3THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG9.6605e-260.4450image
chr6:158973317-158977135:-THYMGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.3795e-040.3721image
ENSG00000130363.10,RSPH3THYMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.3364e-040.3601image
chr6:158973317-158977135:-UCECGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.7295e-050.3277image
ENSG00000130363.10,RSPH3UCECGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.8331e-050.3147image
ENSG00000130363.10,RSPH3UCSGSVA_HALLMARK_GLYCOLYSISEAG7.4390e-050.5083image
chr6:158973317-158977135:-UCSGSVA_HALLMARK_GLYCOLYSISEER6.1386e-050.5133image
ENSG00000130363.10,RSPH3UVMGSVA_HALLMARK_MYC_TARGETS_V1EAG9.3705e-03-0.3640image
chr6:158973317-158977135:-UVMGSVA_HALLMARK_MYC_TARGETS_V1EER9.3705e-03-0.3640image


Top

7. Enriched editing regions and drugs for RSPH3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr6:158973317-158977135:-ACCAZD.0530EER1.5917e-020.2739image
ENSG00000130363.10,RSPH3ACCAZD.0530EAG1.5917e-020.2739image
chr6:158973317-158977135:-BLCACGP.082996EER4.1214e-12-0.3524image
ENSG00000130363.10,RSPH3BLCACGP.082996EAG2.5195e-11-0.3395image
chr6:158973317-158977135:-BRCACGP.082996EER4.0639e-15-0.2365image
ENSG00000130363.10,RSPH3BRCACGP.082996EAG9.9622e-16-0.2416image
ENSG00000130363.10,RSPH3CESCCI.1040EAG5.9517e-05-0.2343image
chr6:158973317-158977135:-CESCCI.1040EER8.7483e-06-0.2591image
ENSG00000130363.10,RSPH3CHOLLenalidomideEAG5.7480e-03-0.4703image
chr6:158973317-158977135:-CHOLGW.441756EER9.9116e-03-0.4425image
ENSG00000130363.10,RSPH3COADCisplatinEAG7.0452e-04-0.2080image
chr6:158973317-158977135:-COADCisplatinEER6.6874e-04-0.2089image
chr6:158973317-158977135:-ESCAGDC.0449EER8.6755e-05-0.3052image
ENSG00000130363.10,RSPH3ESCAGDC.0449EAG6.9433e-05-0.3092image
ENSG00000130363.10,RSPH3GBMAG.014699EAG1.4046e-020.1951image
chr6:158973317-158977135:-GBMAG.014699EER1.2437e-020.1984image
ENSG00000130363.10,RSPH3HNSCCI.1040EAG1.1760e-12-0.3230image
chr6:158973317-158977135:-HNSCCI.1040EER1.1263e-12-0.3233image
chr6:158973317-158977135:-KICHJNK.Inhibitor.VIIIEER5.3597e-07-0.5753image
ENSG00000130363.10,RSPH3KICHJNK.Inhibitor.VIIIEAG5.3597e-07-0.5753image
ENSG00000130363.10,RSPH3KIRCCI.1040EAG7.2778e-11-0.3249image
chr6:158973317-158977135:-KIRCCI.1040EER3.9715e-12-0.3447image
ENSG00000130363.10,RSPH3KIRPAZD.2281EAG1.8302e-08-0.3246image
chr6:158973317-158977135:-KIRPAZD.2281EER1.8674e-08-0.3244image
chr6:158973317-158977135:-LAMLKU.55933EER2.1222e-02-0.2156image
ENSG00000130363.10,RSPH3LAMLKU.55933EAG2.0685e-02-0.2165image
ENSG00000130363.10,RSPH3LGGDocetaxelEAG1.6709e-100.2775image
chr6:158973317-158977135:-LGGDocetaxelEER4.3393e-100.2713image
chr6:158973317-158977135:-LIHCDMOGEER1.7798e-03-0.2320image
ENSG00000130363.10,RSPH3LIHCDMOGEAG2.6782e-03-0.2201image
ENSG00000130363.10,RSPH3LUADGemcitabineEAG2.1919e-09-0.2677image
chr6:158973317-158977135:-LUADGemcitabineEER8.4458e-10-0.2743image
chr6:158973317-158977135:-LUSCCyclopamineEER9.0898e-05-0.1811image
ENSG00000130363.10,RSPH3LUSCCyclopamineEAG1.0546e-04-0.1794image
chr6:158973317-158977135:-MESODoxorubicinEER1.4075e-02-0.2753image
ENSG00000130363.10,RSPH3MESODoxorubicinEAG1.5792e-02-0.2708image
ENSG00000130363.10,RSPH3OVGNF.2EAG3.3286e-07-0.2953image
chr6:158973317-158977135:-OVEmbelinEER4.6491e-100.3571image
ENSG00000130363.10,RSPH3PAADJNJ.26854165EAG1.6409e-040.2827image
chr6:158973317-158977135:-PAADJNJ.26854165EER1.4697e-040.2847image
ENSG00000130363.10,RSPH3PCPGAxitinibEAG8.8188e-040.2478image
chr6:158973317-158977135:-PCPGAxitinibEER1.1836e-030.2418image
ENSG00000130363.10,RSPH3PRADBMS.536924EAG8.7109e-09-0.2555image
chr6:158973317-158977135:-PRADBMS.536924EER8.8503e-09-0.2554image
ENSG00000130363.10,RSPH3READElesclomolEAG1.0231e-04-0.3960image
chr6:158973317-158977135:-READElesclomolEER1.0231e-04-0.3960image
chr6:158973317-158977135:-SARCMethotrexateEER2.9750e-08-0.3637image
ENSG00000130363.10,RSPH3SARCMethotrexateEAG4.3018e-08-0.3598image
ENSG00000130363.10,RSPH3SKCMCI.1040EAG5.1292e-04-0.1847image
chr6:158973317-158977135:-SKCMCI.1040EER6.2661e-05-0.2135image
chr6:158973317-158977135:-STADImatinibEER9.5611e-050.2020image
ENSG00000130363.10,RSPH3STADImatinibEAG1.0911e-040.2003image
chr6:158973317-158977135:-TGCTLenalidomideEER9.4271e-04-0.3921image
ENSG00000130363.10,RSPH3TGCTLenalidomideEAG1.0130e-03-0.3899image
chr6:158973317-158977135:-THCACI.1040EER1.4888e-28-0.4674image
ENSG00000130363.10,RSPH3THCACI.1040EAG5.9700e-28-0.4627image
chr6:158973317-158977135:-THYMMidostaurinEER1.2783e-050.4212image
ENSG00000130363.10,RSPH3THYMMidostaurinEAG1.4256e-050.4191image
chr6:158973317-158977135:-UCECCGP.60474EER9.9988e-05-0.2982image
ENSG00000130363.10,RSPH3UCECCGP.60474EAG2.4998e-04-0.2815image
ENSG00000130363.10,RSPH3UCSCGP.60474EAG2.2314e-03-0.4038image
chr6:158973317-158977135:-UCSBortezomibEER1.5548e-03-0.4166image
ENSG00000130363.10,RSPH3UVMDoxorubicinEAG1.4926e-020.3424image
chr6:158973317-158977135:-UVMDoxorubicinEER1.4926e-020.3424image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType